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Abstract
Background: Total hip arthroplasty (THA) is a common procedure associated with moderate postoperative pain. No
nerve block without loss of motor function has been documented for THA. We hypothesised that an ultrasound-
guided lateral femoral cutaneous nerve (LFCN) block added to a multimodal postoperative pain regimen would
reduce postoperative pain after THA.
Methods: One hundred patients who had a THA by the posterior approach were evaluated in this randomised,
placebo-controlled, blinded, parallel-group trial comparing an ultrasound-guided LFCN-block with either 8 ml of
ropivacaine, 7.5 mg/ml, (Group Ropivacaine) or 8 ml of saline (Group Placebo) given postoperatively. Surgery was
performed under spinal anaesthesia. The primary outcome was pain (measured on a Visual Analogue Scale (VAS))
4 h post-blockade during 30° flexion of the hip. Secondary outcomes were pain at rest, pain during movement,
oxycodone consumption (0–24 h), time to mobilisation, ability to mobilise, and length of stay. Patients, assessors
and all staff involved with patient care were blinded to the intervention.
Results: There was no difference in primary outcome between Group Ropivacaine and Group Placebo (VAS 27 mm
vs. 31 mm, p = 0.41; difference −5 mm (95 % CI: −15 mm - +5 mm). No differences in any of the secondary
outcomes were observed. No adverse events, or harms, were observed during the trial.
Conclusion: Pain scores, opioid use, time to mobilisation, and length of stay were low in both Group Ropivacaine
and Group Placebo. We found no added analgesic effect of a LFCN-block when combined with paracetamol and
ibuprofen after THA by the posterior approach.
Trial registration: EudraCT: 2013-004501-12 (December 16th 2013)
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Background
There is no gold standard for pain management after
total hip arthroplasty (THA) [1, 2]. Early mobilisation is
the main priority [3] and different combinations of non-
opioid drugs, peripheral nerve blocks, epidural analgesia
and local infiltration analgesia (LIA) are used to reduce
opioid requirements and opioid-related adverse effects.
THA is a very common procedure and most patients are
elderly and thus have a lower tolerance of opioid related
side-effects.
Wound pain may play a role in pain after THA. It has
been demonstrated that the size of the incision is dir-
ectly related to postoperative pain and minimal incision
THA is shown to reduce postoperative pain [4, 5]. Local
wound infiltration has been used as part of an analgesic
regimen for THA, but its place in postoperative pain
management is debated [6–8]. A recent systemic review
concludes that LIA have limited additional analgesic
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efficacy in THA when combined with a multimodal an-
algesic regimen consisting of paracetamol, celecoxib and
gabapentin [6].
Peripheral nerve blocks used for postoperative pain
management after THA include femoral nerve block,
fascia iliaca block and lumbar plexus block [1]. All have
analgesic effects but these peripheral nerve blocks are
associated with motor blockade and may lead to falling
[9]. The priority of early mobilisation warrants a pure
sensory block.
The lateral femoral cutaneous nerve (LFCN) is a sen-
sory branch from the lumbar plexus and has a highly
variable course and supplies parts of the lateral and an-
terior upper thigh [10–15]. The LFCN-block is a pure
sensory block and seeks to remove wound pain after
THA. Ultrasonic guided LFCN-block has never been in-
vestigated as a part of multimodal analgesic regimen for
THA.
The aim of this placebo controlled trial was to investigate
the effects of LFCN-block on pain, opioid requirements
and mobilisation in patients receiving a basic analgesic regi-
men consisting of paracetamol and ibuprofen after THA.
We hypothesised that LFCN-block would reduce pain dur-
ing movement 4 h after LFCN-block (primary outcome)
without delaying mobilisation.
Methods
This prospective, randomised, placebo-controlled trial was
approved by the Danish Medicine Agency, (EudraCT
registration number: 2013-004501-12, December 16th
2013), the local Regional Ethics Committee, Region
Zealand, Allén 15, 4180 Sorø, (SJ-367, Chairperson: Knud
Rasmussen, on December 16th 2013) and the Danish Data
Protection Agency. The Copenhagen University Good
Clinical Practice Unit monitored the trial. The trial was
conducted at Næstved Hospital, Næstved, Denmark and
registered at clinicaltrials.gov (NCT02289937) on
November 12th 2014.
All patients provided written informed consent before
participating. Eligible participants were patients scheduled
for primary THA under spinal anaesthesia. Exclusion cri-
teria were general anaesthesia, allergy against local anaes-
thetics, revision arthroplasty, bilateral arthroplasty, fertile
women and patients with daily use of opioids.
Randomisation was based on a computer-generated
randomisation list, in a ratio of 1:1. The randomisation
list and sealed, opaque envelopes were made by a secre-
tary with no further involvement in this trial. Upon in-
clusion, subjects received treatment assigned according
to the randomisation list, in consecutive numbered,
opaque, sealed envelopes.
The study medication was prepared by a nurse accord-
ing to the randomisation list. This was verified by a sec-
ond nurse. These nurses were not further involved in
treating the patient, or in the trial. The study medication
was prepared in a syringe and labelled with the patient’s
id-number and the number according to the randomisa-
tion list. Ropivacaine and saline are visually
indistinguishable.
All investigators, patients, outcome assessors, and
clinical personnel were blinded to the intervention.
All subjects received a primary hip arthroplasty. This
was either cemented, uncemented or hybrid using the
posterior approach. No LIA was used. The subjects
were anaesthetised with spinal anaesthesia induced
with 2–2.5 ml isobaric 0.5 % bupivacaine. Sedation
with propofol or remifentanil was administered at the
discretion of the anaesthesiologist. In the case of fail-
ure of the spinal anaesthesia and conversion to general
anaesthesia the participant would be removed from the
trial and replaced.
The LFCN-blocks were performed in the post an-
aesthesia care unit when the subjects were able to
move their toes but before the spinal anaesthesia
had worn off (defined as T0). The subjects received
an active or placebo LFCN-block according to ran-
domisation. The LFCN-blocks were performed by
anaesthesiologists specially trained and certified to
the procedure.
A high-frequency linear ultrasound transducer
(15–6 MHz) was used to scan the area (Sonosite S-
nerve). The study medicine was administrated as a bolus
of 8 ml 7.5 mg/ml ropivacaine or 8 ml isotonic saline. We
identified the LFCN between the fascia lata and the fascia
iliaca (Fig. 1) by scanning lateral-to-medial from the anter-
ior superior iliac spine along the inguinal ligament. Before
needle insertion the femoral nerve, vein and artery were
located to avoid complications. The needle (B-Braun
Ultraplex, 22G × 80 mm) was introduced in-plane from
lateral-to-medial. Correct needle placement was con-
firmed with bolus’ of 1–2 ml saline at the discretion of the
anaesthesiologist. The correct spread of the bolus around
the LFCN was observed.
Postoperative pain treatment consisted of 1 g of para-
cetamol administrated orally at 6 h intervals and 600 mg
of ibuprofen administrated orally at 8 h intervals initi-
ated immediately after the surgery. Opioids were admin-
istrated by the nurses if the patients scored more than
30 mm on a Visual Analogue Scale (VAS), or when re-
quested by the patient. The opioid used was oxycodone,
either orally or intravenous.
The primary outcome was difference in pain between
the groups during 30 ° flexion of the hip at four hours
after T0 (T4). Secondary outcomes were pain at rest
and during 30 ° flexion of the hip at T0, T1, T2, T4, T8,
T12 and T24 (corresponding 0, 1, 2, 4, 8, 12, and 24 h
after T0), cumulative oxycodone consumption (0–24 h
postoperatively), time to first administration of oxycodone,
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length of hospital stay, time to mobilisation and ability to
mobilise.
We assessed pain with the VAS-score (0–100 mm;
0 mm, no pain; 100 mm, worst pain imaginable) at rest
and during 30 ° active flexion of the hip. The mobilisation
ability was assessed using the Cumulated Ambulation
Score (CAS; 0–6, 0, no mobilisation; 6 fully mobilised)
[16, 17]. Opioid administrations were collected from the
electronic patient chart.
Data handling and statistics
A difference of 20 mm in VAS-scores at T4 during 30 °
flexion of the hip between the two groups was considered
clinical relevant. From the literature we found a standard
deviation (SD) of 30 mm [18]. With a type I error (alfa) of
5 % and a power (1 – beta) of 80 %, 2 × 36 patients were
needed. To account for the uncertainty of the true SD and
to gain more power we included 2 × 50 evaluable patients.
Data were analysed using IBM SPSS Statistics version
21 for Windows (SPSS, Chicago, Illinois, USA). We used
Shapiro-Wilks test to test for normality of our data. Data
are presented as mean and SD, or median and first and
third quartile as appropriate. For comparison of our
non-parametric data we used Mann-Whitney U-test and
the Hodges-Lehman estimator. A two-sided p < 0.05 was
considered statistical significant. Bonferroni correction
was used for multiple comparisons.
After completion of the trial the data were typed into
a spreadsheet by two investigators and compared for
typos. A randomisation list assigning subjects to either
group “a” or “b” was provided without revealing the
identity of the groups. The statistical analysis had been
performed and conclusions were drawn before it was
revealed which group was ropivacaine and which was
placebo.
Results
One hundred twenty subjects were enrolled in the study
from 3rd of March 2014 to 1st of October 2014 in order
to reach the pre-specified number of 100 patients be-
cause 20 did not complete the study (Fig. 2). Thus, one
hundred subjects were evaluated (47 in Group Ropiva-
caine and 53 in Group Placebo). The subjects’ character-
istics did not differ between the two groups (Table 1).
Twenty subjects were excluded from the trial for vari-
ous reasons. These were distributed equally between the
ropivacaine and placebo group. Reasons for exclusion
were administration of opioids other than prescribed in
the study protocol, inadequate spinal anaesthesia with
conversion to general anaesthesia, or daily use of opioids
prior to surgery that the patient neglected to inform the
investigators about until after the surgery.
The VAS-scores at T4 during 30 ° flexion of the hip
were 31 and 26.5 mm in the Group Placebo and the
Group Ropivacaine, respectively, and the difference was
−5 mm (95 % CI: −15 - +5 mm), p = 0.41.
Due to unforeseen difficulties obtaining data for all
subject we had only few VAS-scores for T8 and T12.
Data for VAS-scores are seen in Figs. 3 and 4.
Oral oxycodone was converted to intravenous oxycodone
(20 mg/7,5 mg) (http://pro.medicin.dk/Laegemiddelgrup-
per/Grupper/227010#a300). The median intravenous-
Fig. 1 Ultrasound image of the lateral femoral cutaneous nerve. LFCN, Lateral Femoral Cutaneous Nerve
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oxycodone consumption was 7 mg (2–13) and 6 mg (2–9),
p = 0.12 in the ropivacaine group and the placebo group, re-
spectively. There was no difference in the time to first
opioid-administration between the two groups (Table 2).
There were missing values for 40 subjects with respect
to the mobility assessment (equally distributed between
groups). Of the remaining 60 subjects there were no dif-
ferences in mobilisation ability (CAS = 5 in both groups,
p = 0.26) or time to first mobilisation (368 vs. 420 min,
p = 0.69).
There were no adverse effects related to the study
medication.
Discussion
This randomised, blinded, placebo-controlled trial com-
paring the analgesic effect of lateral femoral cutaneous
nerve block on pain after total hip arthroplasty by the pos-
terior approach showed no differences between the two
groups regarding pain scores, neither during movement,
nor at rest, during the first 24 h postoperatively. In
addition we observed no differences in opioid require-
ments. To our knowledge, this is the first prospective trial
to evaluate ultrasound-guided LFCN-block for THA.
The median pain scores, both during movement and
at rest, were low in both groups, which was unexpected.
Fig. 2 Flow-chart
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In our search of the literature we found a median VAS-
score during walking of 50 mm the first postoperative
day [19, 20]. Moderate pain corresponds to VAS-score =
30 mm and is considered to provide adequate sensitivity
in acute pain trials [21–23]. The median pain score during
flexion of the hip at 4 h postoperatively in our control
group is barely “moderate pain”, and perhaps our trial did
not have sufficient sensitivity to detect the effect of any
analgesic intervention.
All subjects in this trial received a basic analgesic regimen
with paracetamol, ibuprofen and oxycodone at request.
This could explain the low pain scores in both groups and
a possible conclusion of this trial could be that this basic
analgesic regimen is sufficient for the majority of patients
after THA. We cannot rule out any benefits in those pa-
tients with more severe pain, and thus further studies are
needed to explore this aspect.
Despite the fact that our sample size calculation was
based on a power of 80 % we do not believe we have
missed any relevant effects of the LFCN-block in this
setting because we decided to include additional patients
to account for the uncertainty of the SD and to give the
trial more power. We believe that 100 subjects are suffi-
cient for this type of trial.
Our study was challenged by a rather large number
of missing data for pain scores at T8 and T12 (40–
60 %). The main reason for this was unforeseen staff
shortage on the ward. Furthermore, many patients
were asleep and we decided not to assign a specific
VAS-score to a sleeping patient. We have chosen
not to show the pain scores for these time points
and not to calculate the Area Under the Curve
(AUC) for the first 24 h because of the lack of data.
Table 1 Basic demographics
Group ropivacaine Group placebo
No patients 47 53
Gender, M 23 25
Age, years 69 (11) 69 (8)
Height, cm 170 (10) 171 (10)





Duration of surgery, min 62 (16) 61 (17)
Duration from end of surgery to
block, min
63 (28) 65 (28)
Age, height, weight, duration of surgery, and duration from end of surgery to
block are mean (SD)
Fig. 3 Pain at rest. For T0, T1, T2, T4, and T24 there are 0, 9, 5, 4, and 16 % missing data respectively, equally distributed between groups. No
differences were statistical significant. VAS, Visual Analogue Scale
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This is an obvious drawback of this study, but we
believe that it does not alter the conclusion of our
study due to the fact that we observed no differ-
ences at T0, T1, T2, T4, and T24.
Another explanation for the lack of significant differ-
ences in pain is block failure. No sensory testing was
performed in this trial. Sensory testing is routine prac-
tice at our institution, but we decided not to perform
this in order to avoid unblinding the trial. Block failure
is a rather unlikely explanation because the LFCN-block
is fairly easy to perform, with a high success rate and
was executed by few anaesthesiologists who were trained
and certified for the procedure.
A number of anatomical variations of LFCN has been
described [10–13], and we cannot be sure that the area
supplied by the LFCN covered the incision in our trial.
A recent study by Davies et al. [14] suggests that LFCN-
block may not cover the expected line of incision for
THA by posterior approach in a large proportion of
cases. Davies et al. concludes that the incision may be
too posterior and extent too superior to be covered by
the LFCN.
Fig. 4 Pain during movement. For T0, T1, T2, T4, and T24 there are 8, 18, 18, 14, and 28 % missing data respectively, equally distributed between
groups. No differences were statistical significant. VAS, Visual Analogue Scale
Table 2 Outcomes
Group Ropivacaine Group Placebo median
Oxycodone consumed the first 24 h, mg 7(2–13) 6 (2–9) P = 0.12
Time to first oxycodone demand, min 253 (144–379) 237 (155–380) P = 1
Cumulated ambulation score the first day 5 (3–6) 5 (4–6) P =0.26
Time from surgery to first ambulation, min 368 (330–519) 420 (364–470) P = 0.69
Length of hospital stay, hours 49 (10) 50 (20) P = 0.53
Values are median and upper and lower quartile or mean and standard deviation. P-values are Mann Whitney U-test
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Conclusion
In conclusion, we demonstrated no additional analgesic
effects of a lateral femoral cutaneous nerve-block when
combined with a basic analgesic regimen with paraceta-
mol, ibuprofen and oxycodone after THA by posterior
approach. Further studies are needed to investigate the
effect of the LFCN-block among patients with higher
pain scores.
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